RECENT APPROACHES INVOLVED IN COLONIC DRUG TARGETING FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A REVIEW
Keywords:Colonic drug targeting, Nucleotide delivery vehicle, Polymeric Nanocarriers, Bioadhesive pellets with pH-sensitive coating, Drug loaded nanoparticles with pH-sensitive coating
The objective of the review is to present the contemporary approaches involved in colonic drug targeting for the therapy of inflammatory bowel disease (IBD). The adverse reactions and side-effects of the conventional drug delivery systems are largely on account of the systemic absorption of the drugs from the small intestine. Moreover, in current drug delivery systems, the drug has to be frequently administered and also in larger doses which greatly reduces patient compliance. Various approaches which are being described here mainly target the colonic region specifically for improved therapy of IBD, by increasing localization and accessibility of the drug to the target site. Also, these approaches will result in the reduction of dose and minimization of adverse effects combined with the use of conventional drug delivery systems.
Marc Fakhoury, Rebecca Negurlij, Armin Mooranian, Hani Al-salami. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res 2014;7:113-20.
Rutgeerts P, Geboes K. Understanding inflammatory bowel disease-the clinician’s perspective. Eur J Surg Suppl 2001;586:66-72.
Vilela EG, Torres HO, Martins FP, Ferrari Mde L, Andrade MM, Cunha AS. Evaluation of inflammatory activity in Crohn’s disease and ulcerative colitis. World J Gastroenterol 2012;18:872-81.
Desai N, Momin M. Colon targeted bioadhesive pellets of curcumin and cyclosporine for improved management of inflammatory bowel disease. Drug Delivery Transl Res 2020;10:1288-301.
Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology 2011;140:1827-37.
K Philip, B Philip. Colon targeted drug delivery systems: a review on primary and novel approaches. Oman Med J 2010;25:79-87.
Sohail M, Mudassir, Minhas MU, Khan S, Hussain Z, de Matas M, et al. Natural and synthetic polymer-based smart biomaterials for management of ulcerative colitis: a review of recent developments and future prospects. Drug Delivery Transl Res 2019;9:595-614.
Rangari TK, Puranik PK. Development of multiparticulate formulation and evaluation of colon targeted drug delivery system of ciprofloxacin: in vivo study with induced colitis model in rats. Asian J Pharm Clin Res 2017;10:167-85.
Rangari TK, Puranik PK. Development of multiparticulate formulation and evaluation of colon targeted drug delivery system of Ketoprofen: in vivo study with induced colitis model in rats and gamma scintigraphy. Asian J Pharm Clin Res 2016;9:234-52.
Laham SAA. The curative effect of methylsulfonylmethane on an experimental model of ulcerative colitis in rats. Int J Curr Pharm Sci 2019;11:51-4.
Ali T, Shakir F, Morton J. Curcumin and inflammatory bowel disease: biological mechanisms and clinical implication. Digestion 2012;85:249–55.
Ali H, Weigmann B, Neurath MF, Collnot EM, Windbergs M, Lehr CM. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases. J Controlled Release 2014;183:167-77.
Agarwal T, Narayana SNGH, Pal K, Pramanik K, Giri S, Banerjee I. Calcium alginate-carboxymethyl cellulose beads for colon targeted drug delivery. Int J Biol Macromol 2015;75:409-17.
Oshi MA, Naeem M, Bae J, Kim J, Lee J, Hasan N, et al. Colon-targeted dexamethasone microcrystals with pH-sensitive chitosan/alginate/Eudragit S multilayers for the treatment of inflammatory bowel disease. Carbohydr Polym 2018;198:434-42.
Dan Chang, Jing Lei, Huiran Cui, Na Lu, Yanjuan Sun, Xiaohua Zhang, et al. Disulfide cross-linked nanospheres from sodium alginate derivative for inflammatory bowel disease: preparation, characterization and in vitro drug release behavior. Carbohydr Polym 2012;88:663-9.
Varum F, Freire AC, Fadda HM, Bravo R, Basit AW. A dual pH and microbiota-triggered coating (Phloral™) for fail safe colonic drug release. Int J Pharm 2020;583:1-8.
Mingzhen Zhang, Emilie Viennois, Meena Prasad, Yunchen Zhang, Lixin Wang, Zhan Zhang, et al. Edible ginger-derived nanoparticles: a novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer. Biomaterials 2016;101:321-40.
Naeem M, Kim W, Cao J, Yoo JW. Enzyme/pH dual sensitive polymeric nanoparticles for targeted drug delivery to the inflamed colon. Collods Surf B 2014:123:271-8.
McConnell EL, Fadda HM, Basit AW. Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm 2008;364:213-26.
Thakral NK, Ray AR, Jacobsen J, Bar-Shalom D, Eriksson AH, Majumdar DK. Colon targeting of fluticasone propionate inclusion complex: a novel approach in inflammatory bowel disease. J Incl Phenom Macrocycl Chem 2013;75:175-84.
Karrout Y, Neut C, Wils D, Siepmann F, Deremaux L. Novel polymeric film coatings for colon targeting: drug release from coated pellets. Eur J Pharm Biopharm 2009;37:427-33.
Karrout Y, Neut C, Wils D, Siepmann F. Peas starch-based film coatings for site-specific drug delivery to the colon. J Appl Polym Sci 2011;119:1176-84.
Karrout Y, Dubuquoy L, Piveteau C, Siepmann F. In vivo efficacy of microbiota-sensitive coatings for colon targeting: a promising tool for IBD therapy. J Controlled Release 2015;197:121-30.
Date AA, Halpert G, Babu T, Ortiz J, Kanvinde P, Dimitrion P, et al. Mucus-penetrating nanosuspension enema for local treatment of inflammatory bowel disease. Biomaterials 2018;185:97-105.
Wilding IR. A scintigraphic study to evaluate what happens to pentasa and asacol in the human gut. Pract Gastroenterol 1999;23:1-8.
Sciarretta G, Furno A, Mazzoni M, Ferrieri A. Scintigraphic study of gastrointestinal transit and disintegration sites of mesalazine tablets labeled with technetium-99m. Scand J Gastroenterol 1993;28:783-5.
Basit AW. Advances in colonic drug delivery. Drugs 2005;65:1991-2007.
Sinha A, Ball D, Connor AL, Nightingale J, Wilding IR. Intestinal performance of two mesalamine formulations in patients with active ulcerative colitis as assessed by gamma scintigraphy. Pract Gastroenterol 2003;27:56-69.
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.
Davis SS, Robertson C, Wilding IR. Gastrointestinal transit of a multiparticulate tablet formulation in patients with active ulcerative colitis. Int J Pharm 1991;68:199-204.
Abrahamsson B, Alpsten M, Jonsson UE, Lundberg PJ. Gastrointestinal transit of a multiple unit formulation (metoprolol CR/ZOK) and a non-disintegrating tablet with emphasis on colon. Int J Pharm 1996;140:229-35.
Patel MM, Amin AF. Development of a novel tablet-in-capsule formulation of mesalamine for inflammatory bowel disease. Pharm Dev Technol 2013;18:390-400.
Travassos WJ, Cheifetz AS. Infliximab: use in inflammatory bowel disease. Curr Treat Options Gastroenterol 2005;8:187-96.
Keithley J, Swanson B. Glucomannan and obesity: a critical review. Altern Ther Health Med 2005;11:30-4.
Huang Z, Gan J, Jia L, Guo G, Wang C, Zang Y, et al. An orally administered nucleotide-delivery vehicle targeting colonic macrophages for the treatment of inflammatory bowel disease. Biomaterials 2015;48:26-36.
Qiao H, Fang D, Chen J, Sun Y, Kang C, Di L, et al. Orally delivered polycurcumin responsive to bacterial reduction for targeted therapy of inflammatory bowel disease. Drug Delivery 2016;24:233-42.
Kesharwani SS, Ahmad R, Bakkari MA, Rajput MKS, Dachineni R, Valiveti CK, et al. Site-directed polymer-drug complexes for inflammatory bowel diseases (IBD): Formulation development, characterization, and pharmacological evaluation. J Controlled Release 2018;290:165-79.
Zhang Q, Tao H, Lin Y, Hu Y, An H, Zhang D, et al. A superoxide dismutase/catalase mimetic nanomedicine for targeted therapy of inflammatory bowel disease. Biomaterials 2016;105:206-21.
Grimpen F, Pavli P. Advances in the management of inflammatory bowel disease. Intern Med J 2010;40:258-64.
Herrlinger K, Wittig B, Stange EF. Chronic inflammatory intestinal diseases. Pathophysiol Ther Int 2009;50:1229-46.
Kornbluth A. Cyclosporine in inflammatory bowel disease. Curr Gastroenterol Rep 1999;1:486-90.
Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease. Gastroenterology 2007;133:312-39.
Melero A, Draheim C, Hansen S, Giner E, Carrerras JJ, Talens Visconti R, et al. Targeted delivery of cyclosporine a by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model. Eur J Pharm Biopharm 2017;119:361-71.
Raftery T, O’Sullivan M. Optimum vitamin D levels in Crohn’s disease: a review. Proc Nutr Soc 2015;74:56-66.
Zai K, Hirota M, Yamada T, Ishihara N, Mori T, Kishimura A, et al. Therapeutic effect of vitamin D3-containing nanostructured lipid carriers on inflammatory bowel disease. J Controlled Release 2018;286:94-102.